Cogent Communications Holdings (CCOI) Appoints Dr. Malvina Eydelman as New CEO for Innovation

CCOI Appoints Dr. Malvina Eydelman as New CEO to Propel Ophthalmic Innovation

The Collaborative Community on Ophthalmic Innovation (CCOI) announces the appointment of Dr. Malvina Eydelman as its new Chief Executive Officer, effective immediately. Dr. Eydelman, a seasoned expert in ophthalmology and medical product innovation, boasts over 30 years of experience at the U.S. Food and Drug Administration (FDA). During her tenure, she has been at the forefront of regulatory initiatives aimed at improving healthcare and patient outcomes. Her collaborative approach has established strong partnerships among industry stakeholders, regulators, clinicians, and patients, all with the goal of accelerating the market entry of safe and effective medical innovations.

Dr. Joel Schuman, President and Chair of the CCOI Board, highlights that Dr. Eydelman's leadership marks a significant step forward in CCOI's mission to enhance global access to ophthalmic care innovations. This appointment comes at a critical time as the demand for advanced ophthalmic solutions continues to grow. With her impressive academic background—including an M.D. from Harvard Medical School, a Doctorate in Health Sciences and Technology from MIT, and an undergraduate degree in Electrical Engineering from The Cooper Union—Dr. Eydelman is well-equipped to lead CCOI into its next phase of innovation.

Throughout her career at the FDA, Dr. Eydelman has spearheaded multidisciplinary teams to ensure the safety and effectiveness of a wide range of medical products, particularly in the fields of ophthalmology, ENT, and anesthesiology. She has played a pivotal role in advancing technologies such as artificial intelligence, premium intraocular lenses (IOLs), and minimally invasive glaucoma surgeries (MIGS). Her involvement in developing regulations and standards for medical products, as well as initiating patient-reported outcome measures, underscores her commitment to fostering innovative solutions in patient care. Dr. Eydelman's leadership is poised to significantly enhance CCOI's objectives in ophthalmic care innovation, ultimately benefiting patients worldwide.

In addition to her extensive work at the FDA, Dr. Eydelman's focus on public-private partnerships and clinical studies demonstrates her dedication to improving health outcomes through collaboration. Her strategic vision for CCOI emphasizes not only the importance of innovation but also the need to engage diverse stakeholders in the ophthalmic community. With this new leadership, CCOI is well-positioned to make impactful advancements in ophthalmic technology and patient care.

As the organization moves forward under Dr. Eydelman’s guidance, the CCOI aims to solidify its role as a pivotal player in the ophthalmic innovation landscape. The future of ophthalmic care looks promising with Dr. Eydelman's wealth of experience and her commitment to enhancing patient access to cutting-edge medical solutions.